Annalisa Morgan

Annalisa Morgan

Auto-generated profile, based on publicly available information

Annalisa Morgan

Department of Neurology, Yale School of Medicine, New Haven, CT, 06510, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Neurology
Verified
Journal Article
Closed access
AMAnnalisa Morgan
Annalisa Morgan
YLYadi Li
Yadi Li
NTNicolas R. Thompson
Nicolas R. Thompson
AMAlex Milinovich
Alex Milinovich
JAJustin Abbatemarco
Justin Abbatemarco
AKAmy Kunchok
Amy Kunchok
Longitudinal outcomes in anti-NMDA receptor encephalitis (anti-NMDARe) are still not fully understood and may not be adequately captured with the modified Rankin Scale (mRS), often the sole reported outcome. We aim to characterize longitudinal outcomes in anti-NMDARe using multiple outcome measures. This single-center, retrospective, observational study examined outcome measures (mRS and Clinical Assessment Scale in Autoimmune Encephalitis [CASE]) in adults with NMDA receptor-IgG in CSF at short- and long-term follow-ups using linear and logistic regression modeling. Patients with evaluations for cognitive impairment (Montreal Cognitive Assessment/Mini-Mental State Examination), depression (Patient Health Questionnaire-9), and anxiety (General Anxiety Disorder-7) >6 months from symptom onset were correlated with final CASE scores. Thirty-eight patients (76% female, median disease onset age = 28 years, range = 1-75 years) were included. The majority received first-line immunosuppressants (97%) at a median of 3.9 weeks (interquartile range [IQR] = 2.1-9.7) from symptom onset and 68% received second-line therapies. At baseline, median/mean mRS and CASE were 4 (IQR = 3-5) and 12.9 (SD = 7.2), respectively. At short-term follow-up (median = 10 weeks, IQR = 6-17), factors associated with higher CASE and mRS included dysautonomia, coma/lethargy, seizures/status epilepticus, and intensive care unit admission (p < 0.05). At long-term follow-up (median = 70 weeks, IQR = 51-174), median/mean mRS and CASE were 2 (IQR = 1-3) and 4.4 (SD = 4.2), respectively. Only weakness at symptom onset predicted higher mRS scores (odds ratio = 5.6, 95% confidence interval 1.02-30.9, p = 0.047). Despite both mRS and CASE improving from baseline (p < 0.001), only 9 patients (31%) returned to their premorbid function. Among patients with cognitive and mood evaluations >6 months from onset, moderate-severe cognitive impairment (42%), depression (28%), and anxiety (30%) were frequent. Cognitive and depression measures were associated with final CASE subscores (including memory, language, weakness, and psychiatric). Multiple clinical factors influenced short-term outcomes, but only onset weakness influenced long-term mRS, highlighting that mRS is predominantly affected by global motor function. Although mRS and CASE improved over time for most patients, these outcome measures did not capture the full extent of long-term functional impairment in terms of mood, cognition, and the ability to return to premorbid function. This emphasizes the need for increased utilization of more nuanced cognitive and mood outcome measures.

15 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
YYYoshiaki Yasumizu
Yoshiaki Yasumizu
NKNamkwon Kim
Namkwon Kim
CRCyprien A. Rivier
Cyprien A. Rivier
JMJeonghyeon Moon
Jeonghyeon Moon
SKShohei Kojima
Shohei Kojima
DHDavid A. Hafler
David A. Hafler
Epstein–Barr virus (EBV) is implicated as a trigger of multiple sclerosis (MS), yet the host genetic mechanisms linking EBV activity to MS is unknown. We performed a cross-ancestry genome-wide association study of EBV DNA positivity (N=617,186), identifying 39 susceptibility risk loci that significantly overlapped with MS risk genes (p=1.3×10 -12 ). Using our single-cell method for EBV detection, we identified 1,069 EBV-infected B cells across 38 individuals. EBV was predominantly in the latent phase and B cell receptor analysis revealed that memory B cell differentiation is altered by infection. Notably, EBV-infected switched memory and atypical B cells upregulated cytokines and costimulatory signals that influence T cell activation, and B cell signaling pathway. Finally, EBV-infected memory B cells upregulated risk genes from both the EBV and MS, suggesting that EBV-infected B cells link T cell modulation to activation of MS susceptibility pathways. These findings define a genetically driven immunologic mechanism underlying MS.

14 March 2024 in The Neurohospitalist
Verified
Journal Article
Closed access
AMAnnalisa Morgan
Annalisa Morgan
VPVineet Punia
Vineet Punia
Multiple medications are known to increase epileptogenicity in patients with and without an underlying seizure disorder. Paradoxically, some of these medications include anti-seizure medications (ASMs) and other medications, such as psychotropics, that act on the central nervous system (CNS). This article aims to discuss 3 clinical cases that highlight the gamut of epileptogenic reactivity secondary to CNS drugs ranging from increased epileptogenicity in the form of interictal epileptiform discharges (IEDs) without seizures, increased epileptogenicity on electroencephalogram (EEG) with associated non-epileptic movement disorders, and frank, de novo seizures. We also analyze the relevant literature on the impact of CNS medications on epileptogenicity.